COST ANALYSIS OF MONOCLONAL ANTIBODIES FOR RHEUMATOID ARTHRITIS USED IN A TERTIARY CARE HOSPITAL

Dr. Shariva Ranadive, Dr. Rajmohan Seetharaman, Dr. Prathamesh Pramod Avad, Dr. Aditya Burje

Abstract


Background: Monoclonal antibodies are costly & are the main reasons for poor compliance in India & with increase in number of monoclonal antibody indications, there can be difficulty in prescribing more cost effective brand to the patient. Therefore it becomes increasingly necessary to examine issues of comparability across different pharmacological agents as well as individual user costs to influence the compliance of patients.

Aim: To evaluate the cost of monoclonal antibodies of different different brand names & to analyse price variation among various anti-cancer drugs available in India.

 

Methodology: The Current Index of Medical Specialities android app containing the latest updates was used to analyze the prices of various monoclonal antibodies. The cost of each molecule of different strengths was tabulated and cost range and % price variation were calculated.

 

Results: A wide range of cost variations were seen among different categories of monoclonal antibodies with maximum price variation was observed in Rituximab injection [128.89%]. The least price variation was seen in Toclizumab  and Secukinumab.

Conclusions: Price control mechanism has an important role and is very much important to reduce the cost burden of treatment particularly in India.


Keywords


comparison, monoclonal antibodies, Indian brands, Current Index of Medical Specialities

Full Text:

PDF

References


Chopra A. Disease burden of rheumatic diseases in India: COPCORD perspective. indian journal of rheumatology. 2015 Jun 1;10(2):70-7.

Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Practice & Research Clinical Rheumatology. 2008 Aug 1;22(4):583-604.

Cohen M, Omair MA, Keystone EC. Monoclonal antibodies in rheumatoid arthritis. International Journal of Clinical Rheumatology. 2013 Oct 1;8(5):541.

Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers. Biologics: targets & therapy. 2016;10:67.

World Health Organization. Promoting rational use of medicines: Core components. WHO Policy Perspectives on Medicine. Geneva: WHO; 2002.

Drug Price Control Order, 2013. Available at http://www.nppaindia.nic.in/en/drugs-prices-control-order-2013/. Accessed 10 June 2019.

Compendium of notified prices of scheduled drugs, 2015. Available at http://www.nppaindia.nic.in/en/drugs-prices-control-order-2013/. Accessed 10 June 2019.


Refbacks

  • There are currently no refbacks.